 |
 |

Long-term Risks of Bisphosphonates Probed
Bridget M. Kuehn
JAMA. 2009;301(7):710-711.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
A growing body of evidence suggests that long-term use of apopular class of drugs for osteoporosis and other bone disorders may be associated with the development of rare complications in some patients.
Bisphosphonate drugs, which stop the resorption of bone, are widely prescribed to treat such conditions as osteoporosis, Paget disease, and certain conditions in cancer patients. However, emerging data show a possible connection between long-term bisphosphonate use and some rare but serious adverse events, such as low-energy femoral fractures (caused by falls from a standing height or less) and osteonecrosis of the jaw. Additionally, a scientist at the US Food and Drug Administration (FDA) recently noted reports of esophageal cancer in patients taking alendronate.
Such reports add to the list of adverse effects already linked to bisphosphonates. In January 2008, the FDA alerted physicians that some patients taking these drugs may experience severe musculoskeletal pain within . . . [Full Text of this Article] FEMORAL FRACTURES
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Flemingia macrophylla Extract Ameliorates Experimental Osteoporosis in Ovariectomized Rats
Ho et al.
Evid Based Complement Alternat Med 2009;0:nep179v1-nep179.
ABSTRACT
| FULL TEXT
|